Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1217389 + Paclitaxel in Advanced Malignancies
NCT02366949Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Primary completion
- Mar 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of BAY 1217389 in solid tumor and triple-negative breast cancer (TNBC) (2 arms), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose, Adverse Events and 2 more. Started Feb 2015; status: completed.
02
Drugs
BAY 1217389
03
Conditions
solid tumortriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02366949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366949.